Thanks for posting the news, Kelt. The addition of ANOTHER gastroenterology guy to the advisory board must mean full speed ahead on using Brilacidin for ulcerative proctitis. And they would NOT be doing that if they didn't have strong evidence that Brilacidin does have strong anti-inflammatory properties in humans.

How would they have that information? A logical conclusion would be: from the Brilacidin-oral mucositis clinical trial, which we know has enrolled patients but data has not been disclosed publicly. And since this is a double-blinded study, the results must be obvious.